Regeneron Pharmaceuticals Director Kathryn Guarini Exercises Options and Sells $340K in Shares

Executive Summary

On September 3, 2026, Regeneron Pharmaceuticals, Inc. ($REGN) filed a Form 4 detailing an insider transaction by Director Kathryn Guarini. On September 2, 2026, Dr. Guarini exercised non-qualified stock options to acquire 400 shares at $719.37 per share and concurrently sold all 400 shares at a price of $850.00 per share, generating total proceeds of $340,000.

Key Transaction Highlights

• Insider Name: Kathryn Guarini
• Role: Director
• Transaction Date: September 2, 2026
• Exercise Price: $719.37
• Sale Price: $850.00
• Shares Sold: 400 shares
• Total Sale Proceeds: $340,000
• Shares Retained Post-Transaction: 603 direct shares of Common Stock (plus 1,158 remaining unexercised options)
• Rule 10b5-1 Plan: Yes, executed pursuant to a pre-scheduled trading plan adopted on February 13, 2026.

Market & Trading Significance

This transaction is categorized as Low Significance. The sale represents a modest volume (400 shares) executed under a pre-established Rule 10b5-1 trading plan. Option exercises paired with immediate dispositions are standard liquidity and portfolio management events for corporate board members and do not indicate a directional bias on company performance.